Strand Therapeutics

Strand had the wonderful opportunity to host some fantastic students from the Princeton Biotech Group during their Boston trip. It was fun to answer questions about mRNA, biotech, being in the clinic, and more! Shoutout to Joseph Lee, Jaspreet Khurana, Joseph Barberio, Aidan Coia, Aidan Simpson, Akshay Mavani, Samta Kundu, and Eva G. for helping out with the tour!

Being a training facilitator who is also a nursing mom isn’t always glamorous, but a huge shoutout to Strand Therapeutics for having the most comfortable, relaxing wellness room complete with the best decor, coloring books, fun books, and fidget toys. If your wellness room is nothing more than a drab closet, it might be time for an upgrade! It’s a small shift, but it shows your employees how important they and their wellness are!

New job posting alert! We're #hiring a Vice President of Clinical Development to join our executive team and facilitate clinical strategy for our lead asset. This will be Strand's first full-time MD hire. Interested? Check out the full job description on our job board: https://lnkd.in/ep6KjKCi #newjob #BioTechNews #BioTech #mRNAResearch #mRNA #mRNATherapies

Last month, some Strands volunteered at The Greater Boston Food Bank. In all, they packed enough groceries to feed a family of four for nearly a year! 🍞🥬🛒 #BioTechNews #BioTech #mRNAResearch #mRNA #mRNATherapies

Shoutout to William P., Aidan Simpson, and Colleen Moran for their poster presentation at the 2024 International Mammalian Synthetic Biology Workshop (mSBW)! They showcased some of Strand's work on synthetic mRNA and genetic circuits. #mSBW2024 #BioTechNews #BioTech #mRNAResearch #mRNA #mRNATherapies AIChE - American Institute of Chemical Engineers

Today is an exciting day of firsts for Strand Therapeutics. We are proud to announce the dosing of our first patient with STX-001 in our first Phase 1 trial for the treatment of cancer patients with solid tumors. STX-001 represents the first-ever programmable mRNA therapy to enter clinical trials. STX-001 is an investigational multi-mechanistic, synthetic self-replicating mRNA technology that expresses an IL-12 cytokine for an extended duration, directly into the tumor microenvironment. Join us at ASCO for more information on the trial design: Presentation Date/Time: 6/1/2024 9:00AM-12:00PM CDT Title: A phase I trial of intratumoral STX-001: A novel self-replicating mRNA expressing IL-12 alone or with pembrolizumab in advanced solid tumors. Session: Developmental Therapeutics -- Immunotherapy Location: McCormick Place, Chicago, Illinois, Hall A Poster Board Number: 161b Permanent Abstract Number: TPS2696 Read our press release: https://lnkd.in/g-j9vq6v #Programmable #mRNA #Oncology #ClinicalTrials #FirstPatientDosed #ASCO24 #ASCO2024

Thrilled to share that Ashlesha Odak, PhD will be presenting breakthrough research at #ASGCT2024! Join us on Friday, 5/10/2024, in the Exhibit Hall to explore the potential of circular RNA-based CAR-T cell therapy for combating cancer. Session Details: Presentation Date/Time: 5/10/2024, Noon - 1:30 PM & 5:30 - 7 PM Title: Circular RNA Based Chimeric Antigen Receptor (CAR) Cell Therapy for Potent and Long-lasting Anti-Tumor Activity Session: Friday Posters: In Vivo Therapy Approaches Presentation Room: Exhibit Hall Abstract #: 1825 This groundbreaking in-body engineering approach promises to revolutionize the landscape of cell therapy, eliminating the traditional complexities associated with ex vivo therapies. By significantly slashing treatment costs and expanding access, this innovative method is set to transform medical care, bringing crucial therapies within reach of more patients. Don’t miss out on how we are advancing the frontiers of cancer treatment with our latest research. #ASGCT24 #CARTherapy #CancerTherapy #InVivoTherapy #BiotechInnovation #Biotech

Excited to announce that Wen Allen Tseng will be presenting our groundbreaking research at #ASGCT2024! Join us on 5/9/2024 in the Exhibit Hall for an in-depth look at STX-003, our latest innovation in programmable mRNA cancer therapy. Session Details: Presentation Date/Time: 5/9/2024, Noon - 1:30 PM & 5:30 - 7 PM Title: STX-003: A Novel Systemically-Delivered mRNA-Based Cancer Therapy Utilizing a Programmable Genetic Circuit Platform for Tumor-Specific Protein Expression and Reduced Toxicity Session: Thursday Posters: Cancer - Immunotherapy and Cancer Vaccines Presentation Room: Exhibit Hall Abstract #: 1272 STX-003 is designed to revolutionize cancer treatment through a programmable genetic circuit platform, enabling tumor-specific protein expression with significantly reduced toxicity. Don’t miss out on how we’re pushing the boundaries of science to fight cancer more effectively. #ASGCT24 #mRNA #CancerTherapy #Immunotherapy #CancerVaccine #BiotechInnovation #Biotech

We are thrilled to announce that we’ve been selected as a spoke of the ARPA-H Investor Catalyst Hub network! 🎉 We are excited to be a part of this nationwide network dedicated to accelerating groundbreaking advances in science and medicine—all in pursuit of better health outcomes for everyone. #ARPAH #ARPANETH #MedTech #HealthTech #InvestorCatalystHub #HealthInnovation

Find out how scientists at Strand Therapeutics are using Benchling to shorten process development cycles — and build curative mRNA therapeutics — by harnessing data at scale. “As a PD scientist, if we have a more holistic view of our historical data, we can create more efficient plans for optimization strategies,” says Mae Kingsbury. https://lnkd.in/eyQHz6Pe #BuiltOnBenchling